Avalo Therapeutics Inc [AVTX] stock is trading at $8.2, down -8.58%. An important factor to consider is whether the stock is rising or falling in short-term value. The AVTX shares have gain 25.38% over the last week, with a monthly amount glided 72.63%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Stifel started tracking the stock with Buy rating on March 25, 2025, and set its price target to $36. On March 25, 2025, Jefferies initiated with a Buy rating and assigned a price target of $23 on the stock. Piper Sandler started tracking the stock assigning a Overweight rating and suggested a price target of $48 on February 28, 2025. Wedbush initiated its recommendation with a Outperform and recommended $18 as its price target on February 21, 2025. BTIG Research started tracking with a Buy rating for this stock on December 19, 2024, and assigned it a price target of $40. In a note dated October 24, 2024, H.C. Wainwright initiated an Neutral rating.
Avalo Therapeutics Inc [AVTX] stock has fluctuated between $3.39 and $16.00 over the past year. Currently, Wall Street analysts expect the stock to reach $23 within the next 12 months. Avalo Therapeutics Inc [NASDAQ: AVTX] shares were valued at $8.2 at the most recent close of the market. An investor can expect a potential return of 180.49% based on the average AVTX price forecast.
Analyzing the AVTX fundamentals
Gross Profit Margin for this corporation currently stands at 1.64% with Operating Profit Margin at -114.32%, Pretax Profit Margin comes in at 165.82%, and Net Profit Margin reading is 165.56%. To continue investigating profitability, this company’s Return on Assets is posted at 0.53, Equity is 1.06 and Total Capital is -0.38.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, Avalo Therapeutics Inc’s Current Ratio is 22.61. On the other hand, the Quick Ratio is 22.61, and the Cash Ratio is 22.27. Considering the valuation of this stock, the price to sales ratio is 201.80, the price to book ratio is 0.72.
Transactions by insiders
Recent insider trading involved Almenoff June Sherie, Director, that happened on Nov 13 ’24 when 500.0 shares were purchased. Director, Almenoff June Sherie completed a deal on Nov 12 ’24 to buy 500.0 shares.
